<DOC>
	<DOCNO>NCT02650752</DOCNO>
	<brief_summary>The purpose study see capecitabine take safely different dos lapatinib patient HER-2 positive breast cancer involve brain ( brain metastasis ) and/or spinal fluid ( leptomeningeal disease ) .</brief_summary>
	<brief_title>Intermittent High-Dose Lapatinib Tandem With Capecitabine HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System ( CNS ) Metastases</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Age ≥18 year Histologicallyconfirmed metastatic adenocarcinoma breast either invasive primary tumor metastatic tissue confirmation HER2+ status define immunohistochemistry ( IHC ) score 3+ , , 2+ confirmatory fluorescence situ hybridization ( FISH ) ratio ≥ 2.0 Received prior trastuzumab chemotherapy metastatic breast cancer except patient CNS site metastatic disease . Radiologic evidence new and/or progressive parenchymal brain metastasis , spinal cord metastasis ( intramedullary ) leptomeningeal disease ( LMD ) magnetic resonance ( MR ) image brain and/or spine , CSF cytology evidence new LMD . Life expectancy &gt; 12 week . ECOG Performance 0 2 Nonescalating corticosteroid dose ( exceed 16 mg daily dexamethasone oral ) ≥ 5 day . Prior therapy : No limit prior therapy last anticancer treatment ≥ 2 week initiation protocolbased therapy provide toxicity ( alopecia ) resolve ≤Grade 1 baseline . For lapatinib IV trastuzumab and/or pertuzumab , washout require . Patients prior whole brain radiation therapy ( WBRT ) stereotactic radiosurgery ( SRS ) eligible , provide new lesion previously treat SRS ≥4 week pass since radiation Patients prior cranial surgery eligible , provide evidence residual disease and/or progression disease ≥4 week pass since surgery . Prior hormonal therapy locally advance metastatic disease allow continue . If everolimus use combination hormonal therapy , , everolimus must discontinue hormonal therapy continue . Continuation intravenous ( IV ) trastuzumab allow patient already IV trastuzumab therapy . Patients previously treat intrathecal ( IT ) trastuzumab allow evidence progression determine treat physician last dose administer ≥ 4 week . Prior capecitabine therapy allow , provide ≥6 month pass since last dose capecitabine . Cardiac ejection fraction lower limit normal measure multigated radionuclide angiography ( MUGA ) scan echocardiogram document ≤ 3 month prior registration . Adequate bone marrow , liver , renal function assess follow : Granulocyte count ≥ 1,000/μL lapatinib &gt; 1,500/uL capecitabine , platelet count ≥ 100,000/μL , hemoglobin ≥ 8 g/dL Serum bilirubin ≤ 1.5 mg/dL ; AST , ALT , alkaline phosphatase ≤ 2.5 × ULN except : Patients hepatic metastasis : ALT AST ≤ 5 × ULN ; patient hepatic and/or bone metastasis : alkaline phosphatase ≤ 5 × ULN patient Gilbert 's disease : serum bilirubin &lt; 5 mg/dL Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min base 24hour urine collection Women childbearing potential must negative serum pregnancy test perform within 14 day prior enrollment . Women childbearing potential men must agree use adequate contraception prior enrollment duration study participation . Patients must able swallow retain oral medication . Contraindications history allergic reaction lapatinib capecitabine , know dihydropyrimidine dehydrogenase deficiency , know hypersensitivity 5fluorouracil . Craniotomy major surgery , open biopsy , significant traumatic injury within 4 week enrollment . Serious , nonhealing wound , infection , ulcer , bone fracture , uncontrolled seizure Significant gastrointestinal disorder diarrhea major symptom ( example Crohn 's disease , ulcerative colitis ) Grade ≥ 2 diarrhea etiology baseline . Active hepatobiliary disease exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis , stable chronic liver disease determine investigator 's assessment . Significant medical comorbidities describe : Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) Unstable angina ( anginal symptom rest ) , newonset angina ( begin within last 3 month ) , myocardial infarction within 6 month prior enrollment , Cardiac ventricular arrhythmia require antiarrhythmic therapy . Known history QTc prolongation Torsades de Pointes Grade 3 hypertension ( SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg despite maximal medical therapy ) Thrombotic , embolic , venous , arterial event cerebrovascular accident include transient ischemic attack within past 6 month . Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Previous concurrent cancer distinct primary site histology breast cancer within 5 year prior enrollment EXCEPT cervical cancer situ , treat nonmelanoma skin cancer , superficial bladder tumor [ Ta Tis ] . Concurrent medication : Rivaroxaban vitaminK antagonist ( e.g. , warfarin ) , enoxaparin allow . No concurrent use strong CYP3A4 inhibitor ( e.g. , ketoconazole , voriconazole , grapefruit ) inducer ( e.g. , phenytoin , carbamazepine , phenobarbital , St. John 's Wort [ Hypericum perforatum ] , dexamethasone dose great 16 mg daily , rifampin [ rifampicin ] , and/or rifabutin ) . 2 week washout period enrollment require strong inducer inhibitor use ( except dexamethasone , dose need 16mg less daily ) . ( Appendix H ) Use concurrent cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine , phenobarbital ) allow . ( Antiepileptic levetiracetam allow ) . Concurrent anticancer therapy ( chemotherapy , hormonal therapy , radiation therapy , surgery , immunotherapy , tumor embolization , biologic therapy include pertuzumab , except IV trastuzumab hormonal therapy , patient already treat either two agent . ) Use investigational drug within 28 day 5 halflives , whichever longer , precede enrollment . Women pregnant breastfeeding . Inability comply protocol /or willing available followup assessment condition investigator 's opinion make patient unsuitable study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lapatinib</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>HER2</keyword>
	<keyword>15-278</keyword>
</DOC>